Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector

Drug Profile

Research programme: anticancer radioimmunotherapeutics - Nordic Nanovector

Alternative Names: 177Lu-conjugated chimeric antibody (anti-CD37 ARC); chHH1 - Nordic Nanovector; Humalutin; Lu-177 chimeric anti-CD37 antibody radionuclide conjugate - Nordic Nanovector; Lu-177-conjugated anti-CD37 chimeric HH1antibody - Nordic Nanovector

Latest Information Update: 07 Jun 2017

Price : $50

At a glance

  • Originator Nordic Nanovector
  • Developer Nordic Nanovector; Norwegian Radium Hospital
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Jun 2017 Preclinical development is ongoing in Norway
  • 24 May 2017 Nordic Nanovector plans a phase I trial for Non Hodgkin's lymphoma in the second half of 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top